Tests a thin nasal scope to examine the upper gut in adults with obesity
Tests a thin nasal endoscope to check the upper gut in adults with obesity.
Key facts
- Who runs it
- Christopher C. Thompson, MD, MSc
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Trans-nasal Endoscopy for Bariatric Patients
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 20 Apr 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transnasal Endoscopy
- Esophagogastroduodenoscopy
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults cared for in a metabolic and bariatric clinic who were referred for an upper endoscopy (a camera exam of the food pipe and stomach).
- Age
- 18 to 90 years (under 90).
- Sex
- All sexes can join.
Main reasons for not taking part
- Under 18 years of age
- A medical reason why EGD or transnasal endoscopy cannot be done
- Cannot give informed consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patient 18 years of age and less than 90 years of age with clinically referred for esophagoscopy, gastroscopy, or esophagogastroduodenoscopy (EGD)
- Cared for in metabolic and bariatric clinic
Who cannot take part
- Patient <18 years of age
- Medically contraindicated to perform EGD or TNE
- Inability to provide informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Michele B. Ryan, MSTaking people
About the trial
What the trial wants to find out
This study plans to learn if the EvoEndo Endoscopy system can be used to evaluate, provide and follow up care for upper gastrointestinal tract diseases in the bariatric population. The smallest current scope available for such a technique is an adult transnasal endoscope with a larger diameter, a pulmonary bronchoscope or Ear Nose and Throat (ENT) laryngoscope. This study is evaluating a newly Food and Drug Administration (FDA) cleared ultra-slim, single-use, endoscope specifically designed for transnasal endoscopy to evaluate its use in adult upper tract gastrointestinal diseases. If such a technique is successful it could improve the safety, cost, and access of endoscopic care for patients in need of an endoscopic evaluation for a bariatric medical condition.
The 2 groups in the trial
- Transnasal Endoscopy (TNE)Existing treatment, for comparison
Unsedated endoscopic evaluation of the esophagus and stomach through the nose with a transnasal endoscope.
Treatment: Transnasal Endoscopy
- Sedated Esophagogastroduodenoscopy (EGD)Existing treatment, for comparison
Sedated endoscopic evaluation of the esophagus and stomach through the mouth with a standard upper endoscope.
Treatment: Esophagogastroduodenoscopy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Use of Sedation-Free Transnasal Endoscopy to Improve Access and Lower Costs of Endoscopic Evaluations in a Bariatric Medical and Surgical Program
- Plain-language title
- Tests a thin nasal scope to examine the upper gut in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06200961, who can take part
- Record updated
- 25 June 2026